APTO-253: Development delayed

Aptose said it will “temporarily delay clinical activities” for its IV APTO-253 to allow the company to investigate

Read the full 186 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE